Clinical management of Staphylococcus aureus bacteremia: a review.
Clinical management of Staphylococcus aureus bacteremia: a review.
复制标题
金黄色葡萄球菌菌血症的临床管理:评论。
DOI:
10.1001/jama.2014.9743
复制
发表时间:
2014-10-01
影响因子:
120.7
通讯作者:
Fowler, Vance G., Jr.
中科院分区:
文献类型:
--
作者:
Holland, Thomas L.;Arnold, Christopher;Fowler, Vance G., Jr.
Several management strategies may improve outcomes in patients with Staphylococcus aureus bacteremia (SAB). The strength of evidence supporting these management strategies, however, varies widely. To perform a systematic review of the evidence for two unresolved questions involving management strategies for SAB: 1) is transesophageal echocardiography (TEE) necessary in all cases of SAB; and 2) what is the optimal antibiotic therapy for methicillin resistant Staphylococcus aureus (MRSA) bacteremia? A PubMed search from inception through May 2014 was performed to find studies that addressed the role of TEE in SAB. A second search of PubMed, EMBASE, and The Cochrane Library from 1/1/1990 to 5/28/2014 was performed to find studies that addressed antibiotic treatment of MRSA bacteremia. Studies that reported outcomes of systemic antibiotic therapy for MRSA bacteremia were included. All searches were augmented by review of bibliographic references from included studies. The quality of evidence was assessed using the GRADE system by consensus of independent evaluations by at least two authors. In 9 studies with a total of 3513 patients, use of TEE was associated with higher rates of diagnosis of endocarditis (14–25%) when compared with TTE (2–14%). Five studies proposed criteria to identify patients in whom TEE might safely be avoided. Only one high-quality trial of antibiotic therapy for MRSA bacteremia was identified from the 83 studies considered. Most contemporary management strategies for SAB are based upon low quality evidence. TEE is indicated in most patients with SAB. It may be possible to identify a subset of SAB patients for whom TEE can be safely avoided. Vancomycin and daptomycin are the first-line antibiotic choices for MRSA bacteremia. Well-designed studies to address the management of SAB are desperately needed.
登录
查看更多内容
影响因子:
14.2
作者:
Forstner, C.;Dungl, C.;Burgmann, H.
通讯作者:
Burgmann, H.
DOI:
10.1016/j.ijantimicag.2011.09.011
发表时间:
2012-01-01
影响因子:
10.8
作者:
Falcone, Marco;Russo, Alessandro;Venditti, Mario
通讯作者:
Venditti, Mario
影响因子:
4.9
作者:
Carugati, Manuela;Bayer, Arnold S.;Chu, Vivian H.
通讯作者:
Chu, Vivian H.
影响因子:
11.8
作者:
Birmingham, MC;Rayner, CR;Schentag, JJ
通讯作者:
Schentag, JJ
影响因子:
11.8
作者:
Cosgrove, SE;Sakoulas, G;Carmeli, Y
通讯作者:
Carmeli, Y